



Association des professionnels
du développement précoce
du médicament

17th CLUB PHASE 1 ANNUAL MEETING

05 April 2018

Paris



Location

Maison de la Chimie
28, rue Saint Dominique
75007 PARIS
France


Phone: (+33)1 40 62 27 00

Access

RER: Line C, Invalides Station

Subway: Lines 8, 12 and 13, Assemblée
Nationale, Solférino or Invalides Stations

Bus: Lines 63, 69, 83, 93 and 94



Registration

Required before **23 March 2018**

Cost (without accommodation)

Club Phase I - 17th annual meeting
only (05 April 2018)

Member (2018): **200 €**

Non-Member: **300 €**

Club Phase I - 17th annual meeting +
PBPK symposium (04 and 05 April
2018)

Member (2018): **300 €**

Non-Member: **400 €**

Limited number of seats

Closest hotels

Saint-Dominique Hotel
62, rue Saint-Dominique

Best Western Tour Eiffel Invalides
35, boulevard de la Tour-Maubourg

Hôtel de Varenne
44, rue de Bourgogne

Booking directly with the Hotel.

Contact

Leclubphase1@gmail.com

Registration form online on

www.clubphase1.fr

Organisation Committee:
Club Phase 1 Board

Club Phase I (Association Loi 1901) a founding member of



Final Programme

08.30-09.00

Welcome coffee/tea

Morning Sessions

09.00-09.10

Welcome from the Club Phase 1 President

09.10-09.50

From biomarkers for patient selection to companion diagnostic in drug development

Gérard Sanderink, Sanofi, France

09.50-10.30

Advances in ECG safety: Phase 1 studies supporting TQT waivers

Pierre Maison-Blanche, Bichat University Hospital, APHP, France

10.30-11.00

Break

11.00-11.40

Metabolite profiling in early clinical drug development: Current status and future prospects

Mike Ufer, Idorsia Pharmaceuticals Ltd, Switzerland

11.40-12.30

PIPs' experience after 10 years: Inclusion of the paediatric development early is necessary when requested by regulation

Sylvie Benchetrit, French referent to the EMA PDCO, France

12.30-14.00

Lunch

Afternoon Sessions

14.00-14.30

Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474

Pr. Mario Van Der Stelt, Leiden University, The Netherlands

14.30-15.00

In silico tools for early phase side effect profiling and off target prediction of potential drug candidates

Pr. Thierry Langer, Prestwick Chemical referent, Vienna University, Austria

15.00-15.20

Panel discussion with Pr. Van Der Stelt, Pr. Thierry Langer and the audience

15.20-15.50

Break

15.50-16.30

CAR T-cell: Engineering immune cells to treat cancer

Roman Galetto, Collectis SA, France

16.30-17.10

Central Nervous System biomarkers with a special focus on electrophysiology

Alain Patat, Biotrial, France

17.10-17.30

Conclusions and presentation of the next events of the Club Phase 1

Club Phase I (Association Loi 1901) a founding member of

